267 related articles for article (PubMed ID: 21800112)
1. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
De Jesus-Acosta A; Oliver GR; Blackford A; Kinsman K; Flores EI; Wilfong LS; Zheng L; Donehower RC; Cosgrove D; Laheru D; Le DT; Chung K; Diaz LA
Cancer Chemother Pharmacol; 2012 Feb; 69(2):415-24. PubMed ID: 21800112
[TBL] [Abstract][Full Text] [Related]
2. The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
Dakik HK; Moskovic DJ; Carlson PJ; Tamm EP; Qiao W; Wolff RA; Abbruzzese JL; Fogelman DR
Cancer Chemother Pharmacol; 2012 Feb; 69(2):425-30. PubMed ID: 21850466
[TBL] [Abstract][Full Text] [Related]
3. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
Fine RL; Fogelman DR; Schreibman SM; Desai M; Sherman W; Strauss J; Guba S; Andrade R; Chabot J
Cancer Chemother Pharmacol; 2008 Jan; 61(1):167-75. PubMed ID: 17440727
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Saif MW; Syrigos K; Penney R; Kaley K
Anticancer Res; 2010 Jul; 30(7):2905-9. PubMed ID: 20683031
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Reni M; Cereda S; Rognone A; Belli C; Ghidini M; Longoni S; Fugazza C; Rezzonico S; Passoni P; Slim N; Balzano G; Nicoletti R; Cappio S; Doglioni C; Villa E
Cancer Chemother Pharmacol; 2012 Jan; 69(1):115-23. PubMed ID: 21626049
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
Sherman WH; Chu K; Chabot J; Allendorf J; Schrope BA; Hecht E; Jin B; Leung D; Remotti H; Addeo G; Postolov I; Tsai W; Fine RL
Cancer; 2015 Mar; 121(5):673-80. PubMed ID: 25492104
[TBL] [Abstract][Full Text] [Related]
7. Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
Ajouz H; Mukherji D; Haydar A; Yakan AS; Saleh A; Elias E; Temraz S; Faraj W; Khalife M; Shamseddine A
J Gastrointest Cancer; 2014 Mar; 45(1):109-12. PubMed ID: 24362621
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
Soares HP; Bayraktar S; Blaya M; Lopes G; Merchan J; Macintyre J; Mayo C; Green MR; Silva O; Levi J; Walker G; Rocha-Lima CM
Cancer Chemother Pharmacol; 2014 Apr; 73(4):839-45. PubMed ID: 24562589
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Middleton G; Silcocks P; Cox T; Valle J; Wadsley J; Propper D; Coxon F; Ross P; Madhusudan S; Roques T; Cunningham D; Falk S; Wadd N; Harrison M; Corrie P; Iveson T; Robinson A; McAdam K; Eatock M; Evans J; Archer C; Hickish T; Garcia-Alonso A; Nicolson M; Steward W; Anthoney A; Greenhalf W; Shaw V; Costello E; Naisbitt D; Rawcliffe C; Nanson G; Neoptolemos J
Lancet Oncol; 2014 Jul; 15(8):829-40. PubMed ID: 24954781
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
Xenidis N; Chelis L; Amarantidis K; Chamalidou E; Dimopoulos P; Courcoutsakis N; Tentes A; Chiotis A; Prassopoulos P; Kakolyris S
Cancer Chemother Pharmacol; 2012 Feb; 69(2):477-84. PubMed ID: 21858532
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
Hill ME; Li X; Kim S; Campbell A; Culler K; Bloomston M; Zalupski M; Hejna G; Bekaii-Saab T
Cancer Chemother Pharmacol; 2011 Mar; 67(3):511-7. PubMed ID: 20461379
[TBL] [Abstract][Full Text] [Related]
12. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
[TBL] [Abstract][Full Text] [Related]
14. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Goel G; Jauhri M; Negi A; Aggarwal S
Hematol Oncol Stem Cell Ther; 2010; 3(2):55-9. PubMed ID: 20543537
[TBL] [Abstract][Full Text] [Related]
15. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
[TBL] [Abstract][Full Text] [Related]
16. [Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
Honda K; Fukuhara T; Kojima Y; Tanaka H; Kushihata F; Kobayashi N
Gan To Kagaku Ryoho; 2006 Dec; 33(13):2089-92. PubMed ID: 17197760
[TBL] [Abstract][Full Text] [Related]
17. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
[TBL] [Abstract][Full Text] [Related]
18. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
Katopodis O; Polyzos A; Kentepozidis N; Giassas S; Rovithi M; Bozionelou V; Kalbakis K; Vamvakas L; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Feb; 67(2):361-8. PubMed ID: 20428874
[TBL] [Abstract][Full Text] [Related]
19. Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.
Hitchen N; Waldron NR; Deva S; Findlay M; Lawrence B
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e231-e238. PubMed ID: 36114593
[TBL] [Abstract][Full Text] [Related]
20. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
